Ascendis Pharma A/s Schedule 13G passive stakes

Artisan Partners, through its various entities, has disclosed beneficial ownership of 4.2% of Ascendis Pharma A/S's ordinary shares as of June 30, 2026.

Janus Henderson Group plc has reported beneficial ownership of 3,719,452 American Depositary Shares, representing 6.0% of the class, in Ascendis Pharma A/S.

Capital International Investors has reported a 3.2% stake in Ascendis Pharma AS, holding 2,013,285 shares as of March 31, 2026.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 10.5% of Ascendis Pharma A/S - ADR.

T. Rowe Price Investment Management, Inc. has reported beneficial ownership of 9.9% of Ascendis Pharma A/S - ADR, holding 6,162,042 shares.

FMR LLC, through its subsidiaries, has disclosed beneficial ownership of 6.6% of Ascendis Pharma AS common stock as of March 31, 2026.

Westfield Capital Management Company, L.P. has reported a beneficial ownership of 8.48% of Ascendis Pharma A/S common stock as of December 31, 2025.

Artisan Partners Asset Management Inc. and its affiliates reported a 5.2% beneficial ownership stake in Ascendis Pharma A/S American Depositary Shares as of December 31, 2025.

T. Rowe Price Investment Management, Inc. filed an amendment to its Schedule 13G, disclosing a 4.8% beneficial ownership in Ascendis Pharma A/S ADR.

Janus Henderson Group plc has filed an Amendment No. 8 to Schedule 13G, reporting a 7.8% beneficial ownership stake in Ascendis Pharma A/S.

T. Rowe Price Investment Management, Inc. has reported a 6.4% beneficial ownership stake in Ascendis Pharma A/S ADR.

Janus Henderson Group plc has increased its beneficial ownership in Ascendis Pharma A/S to 8.0% of American Depositary Shares, holding 4,427,792 shares.

Capital International Investors has disclosed a 5.6% beneficial ownership stake in Ascendis Pharma AS, holding over 3.1 million common shares.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a beneficial ownership of 7.4% in Ascendis Pharma A/S as of March 31, 2025.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, revealing a 5.0% beneficial ownership stake in Ascendis Pharma A/S American Depositary Receipts (ADRs).

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have filed an amended Schedule 13G, reporting a beneficial ownership of 8.0% of Ascendis Pharma AS's common stock as of March 31, 2025.

Janus Henderson Group plc has filed an Amendment No. 5 to its Schedule 13G, reporting a beneficial ownership of 7.2% in Ascendis Pharma A/S as of December 31, 2024.

Westfield Capital Management Company, L.P. has disclosed a significant 9.18% beneficial ownership stake in Ascendis Pharma A/S, as reported in its latest Schedule 13G filing.

Westfield Capital Management Company, L.P. has disclosed a 9.18% beneficial ownership stake in Ascendis Pharma A/S as of December 31, 2024, indicating a passive investment.